Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C†
Version of Record online: 24 JUL 2007
Copyright © 2007 American Association for the Study of Liver Diseases
Volume 46, Issue 2, pages 324–329, August 2007
How to Cite
Pockros, P. J., Schiff, E. R., Shiffman, M. L., McHutchison, J. G., Gish, R. G., Afdhal, N. H., Makhviladze, M., Huyghe, M., Hecht, D., Oltersdorf, T. and Shapiro, D. A. (2007), Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology, 46: 324–329. doi: 10.1002/hep.21664
Potential conflict of interest: Dr. Shapiro is an employee and owns stock in Idun Pharmaceuticals. He is also a consultant for Pfizer, Inc. Dr. Oltersdorf is an employee and owns stock in Idun Pharmaceuticals. Dr. Pockros is a consultant for, advises, and received grants from Idun Pharmaceuticals. Dr. Schiff is a consultant for, received grants, and is on the speakers' bureau of Gilead, Ortho-Biotech, and Schering-Plough. He is also a consultant and received grants from Abbott, Bristol-Myers Squibb, Cadence Pharmaceuticals, GlaxoSmithKline, Idenix, Prometheus, Roche Molecular, and SciClone Pharmaceuticals. He is a consultant for Achillion Pharmaceutical, Cadence Pharmaceuticals, GlobeImmune, Inc., Pharmasset, Inc., Pfizer, Salix Pharmaceuticals, Inc., and Novartis/Idenix. Dr. Shiffman is a consultant and received grants from Idun Pharmaceuticals and Pfizer. Dr. McHutchison received grants from Idun Pharmaceuticals and Pfizer. Dr. Gish received grants, is a consultant, and is on the speakers' bureau of Bristol Myers Squibb, Eximias, F. Hoffmann-LaRoche Ltd., Gilead Sciences, InterMune Pharmaceuticals, Ortho Biotech, Schering-Plough Corp., SciClone Pharmaceuticals, Valeant Pharmaceuticals, PowderMed, and GlobeImmnue. He also received grants from Pfizer, Idun Pharmaceuticals, and Idenix/Novartis. He is also a consultant and is on the speakers' bureau for Bayer AG and GlaxoSmithKline. He is a consultant for Amgen Inc., Anadys Pharmaceuticals, Inc., Chiron Corp., Corixa Corp., Human Genome Sciences, Metabasis Therapeutics, United Therapeutics, XTL Biopharmaceuticals, Zymogenetics, Inc., Pharmaseet, Idenix, Hepahope, Nucleonics, and Innogenetics. He is on the speakers' bureau of Salix. Dr. Afdhal advises and received grants from Idun Pharmaceuticals.
- Issue online: 27 JUL 2007
- Version of Record online: 24 JUL 2007
- Manuscript Accepted: 22 JAN 2007
- Manuscript Received: 20 NOV 2006
- Idun Pharmaceuticals, Inc., now owned by Pfizer, Inc.
- 6Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 2001; 8: 406–413., , , , .